A Retrospective Study of Hepatitis C Virus Carriers in a Local Endemic Town in Japan. A Possible Presence of Asymptomatic Carrier

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 1995 Feb 1

PMID 7851213

Citations 4

Authors

S Ohkoshi

H Tawaraya

K Kuwana

T Harada

M Watanabe

S Higuchi

H Kojima

T Kamimura

H Asakura

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis, cirrhosis, and hepatocellular carcinoma are the accepted sequelae of chronic hepatitis C virus (HCV) infection. However, the real natural history of HCV infection is not still well understood. To approach this problem, we investigated 91 individuals positive for antibodies against HCV (anti-HCV), who have received annual liver function examination in a local town known to have had high carrier rates of hepatitis B virus (HBV) and HCV. Among the 91 anti-HCV-positive individuals, 63 had undertaken the annual examination more than five times in the past 14 years. We analyzed retrospectively the past liver function test results of these 63 subjects and evaluated their present virological status by determining HCV genotypes and estimating quantity of HCV RNA in the sera. Among the 63 subjects, 50 (79.4%) had HCV RNA in the serum and 40 (80%) of the 50 subjects with HCV RNA had abnormal alanine aminotransferase or aspartate aminotransferase level more than once in their records. However, the other 10 (20%) had no abnormal levels during the period examined. Six of 50 (12%) had ultrasonographic findings suggestive of cirrhosis. Thus, HCV-infected individuals in this area did not seem to have progressive liver diseases. Considering the advanced ages of the individuals examined (mean 64 years old), we may have observed a stage in the natural history of HCV infection in which viremia persists in most individuals and the tendency to progress to serious chronic liver disease is mild.

Citing Articles

Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.

Uto H, Stuver S, Hayashi K, Kumagai K, Sasaki F, Kanmura S Hepatology. 2009; 50(2):393-9.

PMID: 19585614 PMC: 4551403. DOI: 10.1002/hep.23002.

Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.

Uto H, Kurogi J, Takahama Y, Kusumoto K, Hayashi K, Ido A J Gastroenterol. 2007; 42(8):673-80.

PMID: 17701131 DOI: 10.1007/s00535-007-2078-0.

Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H Dig Dis Sci. 2002; 47(1):170-6.

PMID: 11837720 DOI: 10.1023/a:1013244326874.

Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.

Montalto G, Zignego A, Ruggeri M, Giannini C, Soresi M, Monti M Dig Dis Sci. 1997; 42(8):1703-7.

PMID: 9286237 DOI: 10.1023/a:1018813532098.

References

Di Bisceglie A, ORDER S, Klein J, WAGGONER J, Sjogren M, Kuo G . The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol. 1991; 86(3):335-8. View

Realdi G, Alberti A, Rugge M, Rigoli A, Tremolada F, Schivazappa L . Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut. 1982; 23(4):270-5. PMC: 1419734. DOI: 10.1136/gut.23.4.270. View

Seeff L, Wright E, Durako S, Alter H, Iber F, Hollinger F . Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992; 327(27):1906-11. DOI: 10.1056/NEJM199212313272703. View

Chung Y, Shong Y . Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol. 1993; 88(2):244-7. View

Alter M, Margolis H, Krawczynski K, Judson F, Mares A, ALEXANDER W . The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327(27):1899-905. DOI: 10.1056/NEJM199212313272702. View

Ohkoshi S, Kojima H, Tawaraya H, Miyajima T, Kamimura T, Asakura H . Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma. Jpn J Cancer Res. 1990; 81(6-7):550-3. PMC: 6504047. DOI: 10.1111/j.1349-7006.1990.tb02605.x. View

Hoofnagle J, Di Bisceglie A, Shindo M . Antiviral therapy of hepatitis C--present and future. J Hepatol. 1993; 17 Suppl 3:S130-6. DOI: 10.1016/s0168-8278(05)80438-6. View

Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y . Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990; 12(4 Pt 1):671-5. DOI: 10.1002/hep.1840120409. View

Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P, Sherlock S . Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994; 19(1):13-8. View

10.

Di Lelio A, Cestari C, Lomazzi A, Beretta L . Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989; 172(2):389-92. DOI: 10.1148/radiology.172.2.2526349. View

11.

Koretz R, Stone O, Gitnick G . The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology. 1980; 79(5 Pt 1):893-8. View

12.

Berman M, Alter H, Ishak K, Purcell R, Jones E . The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med. 1979; 91(1):1-6. DOI: 10.7326/0003-4819-91-1-1. View

13.

Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L . Persistent hepatitis C viraemia without liver disease. Lancet. 1993; 341(8843):464-5. DOI: 10.1016/0140-6736(93)90210-8. View

14.

Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. DOI: 10.1126/science.2523562. View

15.

Gilliam 3rd J, Geisinger K, Richter J . Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med. 1984; 101(6):794-5. DOI: 10.7326/0003-4819-101-6-794. View

16.

Colombo M, Kuo G, Choo Q, Donato M, Del Ninno E, Tommasini M . Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989; 2(8670):1006-8. DOI: 10.1016/s0140-6736(89)91016-7. View

17.

Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M . Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25):1575-8. DOI: 10.1056/NEJM198612183152503. View

18.

Farci P, Alter H, Wong D, Miller R, Shih J, Jett B . A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991; 325(2):98-104. DOI: 10.1056/NEJM199107113250205. View

19.

Kato N, Yokosuka O, Hosoda K, Ito Y, OHTO M, Omata M . Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993; 18(1):16-20. View

20.

Koretz R, Suffin S, Gitnick G . Post-transfusion chronic liver disease. Gastroenterology. 1976; 71(5):797-803. View